First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity.

@article{Bruderer2015FirstinhumansSO,
  title={First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity.},
  author={Shirin Bruderer and No{\'e}mie Hurst and Ruben de Kanter and Tommaso Miraval and Thomas Pfeifer and Yves Donazzolo and Jasper Dingemanse},
  journal={Antimicrobial agents and chemotherapy},
  year={2015},
  volume={59 2},
  pages={935-42}
}
Emerging resistance to antimalarial agents raises the need for new drugs. ACT-451840 is a new compound with potent activity against sensitive and resistant Plasmodium falciparum strains. This was a first-in-humans single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of ACT-451840 across doses of 10, 50, 200, and 500 mg… CONTINUE READING